Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) (extension) | 0.24 [0.03, 2.28] | | < 1 | | 0% | 1 study (1/-) | 89.2 % | NA | not evaluable | | important | - |
pCR | 1.45 [0.80, 2.63] | | > 1 | | 0% | 1 study (1/-) | 88.9 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE leading to death (grade 5) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
SAE (any grade) | 0.88 [0.47, 1.66] | | < 1 | | 0% | 1 study (1/-) | 64.9 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
hepatitis (Autoimmune) AE (grade 3-4) | 1.79 [0.06, 54.10] | | < 1 | | 0% | 1 study (1/-) | 37.1 % | NA | not evaluable | | non important | - |
Abdominal pain AE (grade 3-4) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Alopecia AE (grade 3-4) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Anaemia AE (grade 3-4) | 0.89 [0.12, 6.46] | | < 1 | | 0% | 1 study (1/-) | 54.6 % | NA | not evaluable | | non important | - |
Arthralgia AE (grade 3-4) | 1.80 [0.16, 20.23] | | < 1 | | 0% | 1 study (1/-) | 31.8 % | NA | not evaluable | | non important | - |
Back pain AE (grade 3-4) | 0.44 [0.01, 13.37] | | < 1 | | 0% | 1 study (1/-) | 67.8 % | NA | not evaluable | | non important | - |
Blood creatinine increased AE (grade 3-4) | 0.05 [0.00, 0.89] | | < 1 | | 0% | 1 study (1/-) | 97.8 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 0.89 [0.05, 14.46] | | < 1 | | 0% | 1 study (1/-) | 53.2 % | NA | not evaluable | | non important | - |
Cough AE (grade 3-4) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 5.49 [0.27, 111.35] | | < 1 | | 0% | 1 study (1/-) | 13.6 % | NA | not evaluable | | non important | - |
Dry skin AE (grade 3-4) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Epistaxis AE (grade 3-4) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 0.47 [0.15, 1.45] | | < 1 | | 0% | 1 study (1/-) | 90.6 % | NA | not evaluable | | non important | - |
Febrile neutropenia AE (grade 3-4) | 1.82 [0.32, 10.20] | | < 1 | | 0% | 1 study (1/-) | 24.9 % | NA | not evaluable | | non important | - |
Headache AE (grade 3-4) | 1.79 [0.06, 54.10] | | < 1 | | 0% | 1 study (1/-) | 37.1 % | NA | not evaluable | | non important | - |
Hyperthyroidism AE (grade 3-4) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Hypophysitis AE (grade 3-4) | 1.79 [0.06, 54.10] | | < 1 | | 0% | 1 study (1/-) | 37.1 % | NA | not evaluable | | non important | - |
Hypothyroidism AE (grade 3-4) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Increase AST AE (grade 3-4) | 5.49 [0.27, 111.35] | | < 1 | | 0% | 1 study (1/-) | 13.6 % | NA | not evaluable | | non important | - |
Increased ALT AE (grade 3-4) | 1.20 [0.26, 5.51] | | < 1 | | 0% | 1 study (1/-) | 40.9 % | NA | not evaluable | | non important | - |
Infusion-related reaction AE (grade 3-4) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Injury, poisoning and procedure AE (grade 3-4) | 0.89 [0.05, 14.46] | | < 1 | | 0% | 1 study (1/-) | 53.2 % | NA | not evaluable | | non important | - |
Leucopenia AE (grade 3-4) | 0.84 [0.45, 1.57] | | < 1 | | 0% | 1 study (1/-) | 70.9 % | NA | not evaluable | | non important | - |
Myalgia AE (grade 3-4) | 1.82 [0.32, 10.20] | | < 1 | | 0% | 1 study (1/-) | 24.9 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 0.06 [0.00, 1.05] | | < 1 | | 0% | 1 study (1/-) | 97.2 % | NA | not evaluable | | non important | - |
Neutropenia AE (grade 3-4) | 0.83 [0.45, 1.52] | | < 1 | | 0% | 1 study (1/-) | 72.8 % | NA | not evaluable | | non important | - |
Peripheral neuropathy AE (grade 3-4) | 0.88 [0.33, 2.33] | | < 1 | | 0% | 1 study (1/-) | 60.2 % | NA | not evaluable | | non important | - |
Pneumonitis AE (grade 3-4) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 0.89 [0.05, 14.46] | | < 1 | | 0% | 1 study (1/-) | 53.2 % | NA | not evaluable | | non important | - |
Stomatitis AE (grade 3-4) | 3.62 [0.16, 81.50] | | < 1 | | 0% | 1 study (1/-) | 21.2 % | NA | not evaluable | | non important | - |
Thrombocytopenia AE (grade 3-4) | 0.44 [0.04, 4.94] | | < 1 | | 0% | 1 study (1/-) | 74.6 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 0.89 [0.05, 14.46] | | < 1 | | 0% | 1 study (1/-) | 53.2 % | NA | not evaluable | | non important | - |